NP-300

NP-300

Cholera-induced Diarrhea

Cholera Infection Icon

Up to
4,000,000 cases
of cholera worldwide1

Deaths Icon

Up to
143,000
deaths1

NP-300 is a second-generation antisecretory agent for symptomatic relief of diarrhea from cholera

Animal Studies Icon

Research & Development

Napo Pharmaceuticals’ Investigational New Drug (IND) application for NP-300 for the symptomatic treatment and relief from infectious diarrhea from pathogens such as Vibrio cholerae, the bacterium that causes cholera, was activated by the US Food and Drug Administration in September 2022. In support of this IND, Napo Pharmaceuticals received partial financial support for certain IND enabling preclinical toxicity studies by the National Institute of Allergy and Infectious Diseases (NIAID). NIAID is part of the National Institutes of Health.

Animal Studies Icon

Research & Development

Napo Pharmaceuticals’ Investigational New Drug (IND) application for NP-300 for the symptomatic treatment and relief from infectious diarrhea from pathogens such as Vibrio cholerae, the bacterium that causes cholera, was activated by the US Food and Drug Administration in September 2022. In support of this IND, Napo Pharmaceuticals received partial financial support for certain IND enabling preclinical toxicity studies by the National Institute of Allergy and Infectious Diseases (NIAID). NIAID is part of the National Institutes of Health.

REGULATORY INFORMATION

The company has previously evaluated the effects of crofelemer for the symptomatic relief and treatment of dehydrating diarrhea in cholera patients at the renowned International Centre for Diarrhoeal Disease Research (ICDDR, B) in Bangladesh. NP-300 and crofelemer have a similar physiological anti-secretory mechanism of action to reduce chloride ion secretion into the gut lumen and improve stool consistency.

Reference: 1. Ali M, Nelson AR, Lopez AL, Sack DA. Updated global burden of cholera in endemic countries. PLoS Negl Trop Dis. 2015;9(6):e0003832. doi:10.1371/journal.pntd.0003832

Regulatory Icon
Regulatory Icon

REGULATORY INFORMATION

The company has previously evaluated the effects of crofelemer for the symptomatic relief and treatment of dehydrating diarrhea in cholera patients at the renowned International Centre for Diarrhoeal Disease Research (ICDDR, B) in Bangladesh. NP-300 and crofelemer have a similar physiological anti-secretory mechanism of action to reduce chloride ion secretion into the gut lumen and improve stool consistency.

Reference: 1. Ali M, Nelson AR, Lopez AL, Sack DA. Updated global burden of cholera in endemic countries. PLoS Negl Trop Dis. 2015;9(6):e0003832. doi:10.1371/journal.pntd.0003832